Success Metrics

Clinical Success Rate
60.0%

Based on 6 completed trials

Completion Rate
60%(6/10)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
4(29%)

Phase Distribution

Ph phase_2
7
50%
Ph not_applicable
2
14%
Ph phase_1
1
7%
Ph phase_3
2
14%
Ph phase_4
2
14%

Phase Distribution

1

Early Stage

7

Mid Stage

4

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
1(7.1%)
Phase 2Efficacy & side effects
7(50.0%)
Phase 3Large-scale testing
2(14.3%)
Phase 4Post-market surveillance
2(14.3%)
N/ANon-phased studies
2(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

54.5%

6 of 11 finished

Non-Completion Rate

45.5%

5 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Active(2)
Completed(6)
Terminated(5)
Other(1)

Detailed Status

Completed6
Terminated4
Not yet recruiting2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.1%)
Phase 27 (50.0%)
Phase 32 (14.3%)
Phase 42 (14.3%)
N/A2 (14.3%)

Trials by Status

unknown17%
not_yet_recruiting214%
terminated429%
withdrawn17%
completed643%

Recent Activity

0 active trials
Showing 5 of 14
not_yet_recruitingnot_applicable

DLBS1033 as Adjunctive Therapy for Patients With Diabetic Neuropathy

NCT07683598
not_yet_recruitingphase_2

The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy

NCT07475065
completedphase_4

Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo

NCT07075289
terminatedphase_2

DLBS1033 for Acute Ischemic Stroke Patients

NCT02133521
terminatedphase_2

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS

NCT02976701
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT07683598Not Applicable

DLBS1033 as Adjunctive Therapy for Patients With Diabetic Neuropathy

Not Yet Recruiting
NCT07475065Phase 2

The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy

Not Yet Recruiting
NCT07075289Phase 4

Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo

Completed
NCT02133521Phase 2

DLBS1033 for Acute Ischemic Stroke Patients

Terminated
NCT02976701Phase 2

Effect of DLBS1033 After Primary PCI in Patients With STE-ACS

Terminated
NCT04425590Phase 2

The Benefit of Add On DLBS1033 for Ischemic Stroke Patient

Unknown
NCT02145988Phase 2

DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease

Terminated
NCT01694537Phase 2

The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers

Completed
NCT01905878Phase 1

Biological Half Life of DLBS1033 in Healthy Volunteers

Completed
NCT02362984Phase 3

DLBS1033 for the Treatment of Acute Ischemic Stroke

Terminated
NCT01865474Phase 4

Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus

Completed
NCT02146664Phase 2

DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization

Withdrawn
NCT01790997Phase 3

Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke

Completed
NCT01378585Not Applicable

Safety and Efficacy of DLBS1033 in Healthy Subjects

Completed

All 14 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
14